

IBS Treatment Market, Global Outlook and Forecast 2022-2028

<https://marketpublishers.com/r/IFD9982022E7EN.html>

Date: April 2022

Pages: 111

Price: US\$ 3,250.00 (Single User License)

ID: IFD9982022E7EN

Abstracts

Irritable bowel syndrome (IBS) is a common disorder that affects the digestive system. IBS is characterized by symptoms such as stomach cramps, bloating, diarrhea, and constipation, which impacts one's everyday life. Although the cause of IBS is unknown, but few factors that cause IBS are severe infection, inflammation in the intestines, muscle contractions in the intestine, changes in bacteria in the gut, and abnormalities in the nerves.

This report contains market size and forecasts of IBS Treatment in Global, including the following market information:

Global IBS Treatment Market Revenue, 2017-2022, 2023-2028, (\$ millions)

Global top five companies in 2021 (%)

The global IBS Treatment market was valued at million in 2021 and is projected to reach US\$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at \$ Million in 2021, While China is Forecast to Reach \$ Million by 2028.

IBS-D Segment to Reach \$ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of IBS Treatment include Allergan (Ireland), Sucampo Pharmaceuticals (U.S.), Ironwood Pharmaceuticals (U.S.), Astellas Pharma (Japan), Bausch Health, Abbott Laboratories (U.S.), Synergy Pharmaceuticals (U.S.), Ardelyx (U.S.) and Nestle (Switzerland), etc. In 2021, the global top five players have a share

approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the IBS Treatment companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global IBS Treatment Market, by Type, 2017-2022, 2023-2028 (\$ millions)

Global IBS Treatment Market Segment Percentages, by Type, 2021 (%)

IBS-D

IBS-C

IBS-M

Global IBS Treatment Market, by Application, 2017-2022, 2023-2028 (\$ millions)

Global IBS Treatment Market Segment Percentages, by Application, 2021 (%)

Hospitals

Clinics

Research Laboratories

Global IBS Treatment Market, By Region and Country, 2017-2022, 2023-2028 (\$ Millions)

Global IBS Treatment Market Segment Percentages, By Region and Country, 2021 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies IBS Treatment revenues in global market, 2017-2022 (estimated), (\$ millions)

Key companies IBS Treatment revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

Allergan (Ireland)

Sucampo Pharmaceuticals (U.S.)

Ironwood Pharmaceuticals (U.S.)

Astellas Pharma (Japan)

Bausch Health

Abbott Laboratories (U.S.)

Synergy Pharmaceuticals (U.S.)

Ardelyx (U.S.)

Nestle (Switzerland)

Sebela Pharmaceuticals (Ireland)

Probi (Sweden)

Alfasigma USA (Italy)

RedHill Biopharma (Israel)

AstraZeneca (U.K)

Ipsen (France)

Novartis (Switzerland)

Takeda Pharmaceutical Company (Japan)

Synthetic Biologics (U.S.)

Protagonist Therapeutics (U.S.)

Pfizer (U.S.)

Lexicon Pharmaceuticals (U.S.)

Innovate Biopharmaceuticals (U.S.)

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

- 1.1 IBS Treatment Market Definition
- 1.2 Market Segments
 - 1.2.1 Market by Type
 - 1.2.2 Market by Application
- 1.3 Global IBS Treatment Market Overview
- 1.4 Features & Benefits of This Report
- 1.5 Methodology & Sources of Information
 - 1.5.1 Research Methodology
 - 1.5.2 Research Process
 - 1.5.3 Base Year
 - 1.5.4 Report Assumptions & Caveats

2 GLOBAL IBS TREATMENT OVERALL MARKET SIZE

- 2.1 Global IBS Treatment Market Size: 2021 VS 2028
- 2.2 Global IBS Treatment Market Size, Prospects & Forecasts: 2017-2028
- 2.3 Key Market Trends, Opportunity, Drivers and Restraints
 - 2.3.1 Market Opportunities & Trends
 - 2.3.2 Market Drivers
 - 2.3.3 Market Restraints

3 COMPANY LANDSCAPE

- 3.1 Top IBS Treatment Players in Global Market
- 3.2 Top Global IBS Treatment Companies Ranked by Revenue
- 3.3 Global IBS Treatment Revenue by Companies
- 3.4 Top 3 and Top 5 IBS Treatment Companies in Global Market, by Revenue in 2021
- 3.5 Global Companies IBS Treatment Product Type
- 3.6 Tier 1, Tier 2 and Tier 3 IBS Treatment Players in Global Market
 - 3.6.1 List of Global Tier 1 IBS Treatment Companies
 - 3.6.2 List of Global Tier 2 and Tier 3 IBS Treatment Companies

4 MARKET SIGHTS BY PRODUCT

- 4.1 Overview

- 4.1.1 by Type - Global IBS Treatment Market Size Markets, 2021 & 2028
- 4.1.2 IBS-D
- 4.1.3 IBS-C
- 4.1.4 IBS-M
- 4.2 By Type - Global IBS Treatment Revenue & Forecasts
 - 4.2.1 By Type - Global IBS Treatment Revenue, 2017-2022
 - 4.2.2 By Type - Global IBS Treatment Revenue, 2023-2028
 - 4.2.3 By Type - Global IBS Treatment Revenue Market Share, 2017-2028

5 SIGHTS BY APPLICATION

- 5.1 Overview
 - 5.1.1 By Application - Global IBS Treatment Market Size, 2021 & 2028
 - 5.1.2 Hospitals
 - 5.1.3 Clinics
 - 5.1.4 Research Laboratories
- 5.2 By Application - Global IBS Treatment Revenue & Forecasts
 - 5.2.1 By Application - Global IBS Treatment Revenue, 2017-2022
 - 5.2.2 By Application - Global IBS Treatment Revenue, 2023-2028
 - 5.2.3 By Application - Global IBS Treatment Revenue Market Share, 2017-2028

6 SIGHTS BY REGION

- 6.1 By Region - Global IBS Treatment Market Size, 2021 & 2028
- 6.2 By Region - Global IBS Treatment Revenue & Forecasts
 - 6.2.1 By Region - Global IBS Treatment Revenue, 2017-2022
 - 6.2.2 By Region - Global IBS Treatment Revenue, 2023-2028
 - 6.2.3 By Region - Global IBS Treatment Revenue Market Share, 2017-2028
- 6.3 North America
 - 6.3.1 By Country - North America IBS Treatment Revenue, 2017-2028
 - 6.3.2 US IBS Treatment Market Size, 2017-2028
 - 6.3.3 Canada IBS Treatment Market Size, 2017-2028
 - 6.3.4 Mexico IBS Treatment Market Size, 2017-2028
- 6.4 Europe
 - 6.4.1 By Country - Europe IBS Treatment Revenue, 2017-2028
 - 6.4.2 Germany IBS Treatment Market Size, 2017-2028
 - 6.4.3 France IBS Treatment Market Size, 2017-2028
 - 6.4.4 U.K. IBS Treatment Market Size, 2017-2028
 - 6.4.5 Italy IBS Treatment Market Size, 2017-2028

- 6.4.6 Russia IBS Treatment Market Size, 2017-2028
- 6.4.7 Nordic Countries IBS Treatment Market Size, 2017-2028
- 6.4.8 Benelux IBS Treatment Market Size, 2017-2028

6.5 Asia

- 6.5.1 By Region - Asia IBS Treatment Revenue, 2017-2028
- 6.5.2 China IBS Treatment Market Size, 2017-2028
- 6.5.3 Japan IBS Treatment Market Size, 2017-2028
- 6.5.4 South Korea IBS Treatment Market Size, 2017-2028
- 6.5.5 Southeast Asia IBS Treatment Market Size, 2017-2028
- 6.5.6 India IBS Treatment Market Size, 2017-2028

6.6 South America

- 6.6.1 By Country - South America IBS Treatment Revenue, 2017-2028
- 6.6.2 Brazil IBS Treatment Market Size, 2017-2028
- 6.6.3 Argentina IBS Treatment Market Size, 2017-2028

6.7 Middle East & Africa

- 6.7.1 By Country - Middle East & Africa IBS Treatment Revenue, 2017-2028
- 6.7.2 Turkey IBS Treatment Market Size, 2017-2028
- 6.7.3 Israel IBS Treatment Market Size, 2017-2028
- 6.7.4 Saudi Arabia IBS Treatment Market Size, 2017-2028
- 6.7.5 UAE IBS Treatment Market Size, 2017-2028

7 PLAYERS PROFILES

7.1 Allergan (Ireland)

- 7.1.1 Allergan (Ireland) Corporate Summary
- 7.1.2 Allergan (Ireland) Business Overview
- 7.1.3 Allergan (Ireland) IBS Treatment Major Product Offerings
- 7.1.4 Allergan (Ireland) IBS Treatment Revenue in Global Market (2017-2022)
- 7.1.5 Allergan (Ireland) Key News

7.2 Sucampo Pharmaceuticals (U.S.)

- 7.2.1 Sucampo Pharmaceuticals (U.S.) Corporate Summary
- 7.2.2 Sucampo Pharmaceuticals (U.S.) Business Overview
- 7.2.3 Sucampo Pharmaceuticals (U.S.) IBS Treatment Major Product Offerings
- 7.2.4 Sucampo Pharmaceuticals (U.S.) IBS Treatment Revenue in Global Market (2017-2022)
- 7.2.5 Sucampo Pharmaceuticals (U.S.) Key News

7.3 Ironwood Pharmaceuticals (U.S.)

- 7.3.1 Ironwood Pharmaceuticals (U.S.) Corporate Summary
- 7.3.2 Ironwood Pharmaceuticals (U.S.) Business Overview

- 7.3.3 Ironwood Pharmaceuticals (U.S.) IBS Treatment Major Product Offerings
- 7.3.4 Ironwood Pharmaceuticals (U.S.) IBS Treatment Revenue in Global Market (2017-2022)
- 7.3.5 Ironwood Pharmaceuticals (U.S.) Key News
- 7.4 Astellas Pharma (Japan)
 - 7.4.1 Astellas Pharma (Japan) Corporate Summary
 - 7.4.2 Astellas Pharma (Japan) Business Overview
 - 7.4.3 Astellas Pharma (Japan) IBS Treatment Major Product Offerings
 - 7.4.4 Astellas Pharma (Japan) IBS Treatment Revenue in Global Market (2017-2022)
 - 7.4.5 Astellas Pharma (Japan) Key News
- 7.5 Bausch Health
 - 7.5.1 Bausch Health Corporate Summary
 - 7.5.2 Bausch Health Business Overview
 - 7.5.3 Bausch Health IBS Treatment Major Product Offerings
 - 7.5.4 Bausch Health IBS Treatment Revenue in Global Market (2017-2022)
 - 7.5.5 Bausch Health Key News
- 7.6 Abbott Laboratories (U.S.)
 - 7.6.1 Abbott Laboratories (U.S.) Corporate Summary
 - 7.6.2 Abbott Laboratories (U.S.) Business Overview
 - 7.6.3 Abbott Laboratories (U.S.) IBS Treatment Major Product Offerings
 - 7.6.4 Abbott Laboratories (U.S.) IBS Treatment Revenue in Global Market (2017-2022)
 - 7.6.5 Abbott Laboratories (U.S.) Key News
- 7.7 Synergy Pharmaceuticals (U.S.)
 - 7.7.1 Synergy Pharmaceuticals (U.S.) Corporate Summary
 - 7.7.2 Synergy Pharmaceuticals (U.S.) Business Overview
 - 7.7.3 Synergy Pharmaceuticals (U.S.) IBS Treatment Major Product Offerings
 - 7.7.4 Synergy Pharmaceuticals (U.S.) IBS Treatment Revenue in Global Market (2017-2022)
 - 7.7.5 Synergy Pharmaceuticals (U.S.) Key News
- 7.8 Ardelyx (U.S.)
 - 7.8.1 Ardelyx (U.S.) Corporate Summary
 - 7.8.2 Ardelyx (U.S.) Business Overview
 - 7.8.3 Ardelyx (U.S.) IBS Treatment Major Product Offerings
 - 7.8.4 Ardelyx (U.S.) IBS Treatment Revenue in Global Market (2017-2022)
 - 7.8.5 Ardelyx (U.S.) Key News
- 7.9 Nestle (Switzerland)
 - 7.9.1 Nestle (Switzerland) Corporate Summary
 - 7.9.2 Nestle (Switzerland) Business Overview
 - 7.9.3 Nestle (Switzerland) IBS Treatment Major Product Offerings

- 7.9.4 Nestle (Switzerland) IBS Treatment Revenue in Global Market (2017-2022)
- 7.9.5 Nestle (Switzerland) Key News
- 7.10 Sebela Pharmaceuticals (Ireland)
 - 7.10.1 Sebela Pharmaceuticals (Ireland) Corporate Summary
 - 7.10.2 Sebela Pharmaceuticals (Ireland) Business Overview
 - 7.10.3 Sebela Pharmaceuticals (Ireland) IBS Treatment Major Product Offerings
 - 7.10.4 Sebela Pharmaceuticals (Ireland) IBS Treatment Revenue in Global Market (2017-2022)
 - 7.10.5 Sebela Pharmaceuticals (Ireland) Key News
- 7.11 Probi (Sweden)
 - 7.11.1 Probi (Sweden) Corporate Summary
 - 7.11.2 Probi (Sweden) Business Overview
 - 7.11.3 Probi (Sweden) IBS Treatment Major Product Offerings
 - 7.11.4 Probi (Sweden) IBS Treatment Revenue in Global Market (2017-2022)
 - 7.11.5 Probi (Sweden) Key News
- 7.12 Alfasigma USA (Italy)
 - 7.12.1 Alfasigma USA (Italy) Corporate Summary
 - 7.12.2 Alfasigma USA (Italy) Business Overview
 - 7.12.3 Alfasigma USA (Italy) IBS Treatment Major Product Offerings
 - 7.12.4 Alfasigma USA (Italy) IBS Treatment Revenue in Global Market (2017-2022)
 - 7.12.5 Alfasigma USA (Italy) Key News
- 7.13 RedHill Biopharma (Israel)
 - 7.13.1 RedHill Biopharma (Israel) Corporate Summary
 - 7.13.2 RedHill Biopharma (Israel) Business Overview
 - 7.13.3 RedHill Biopharma (Israel) IBS Treatment Major Product Offerings
 - 7.13.4 RedHill Biopharma (Israel) IBS Treatment Revenue in Global Market (2017-2022)
 - 7.13.5 RedHill Biopharma (Israel) Key News
- 7.14 AstraZeneca (U.K.)
 - 7.14.1 AstraZeneca (U.K.) Corporate Summary
 - 7.14.2 AstraZeneca (U.K.) Business Overview
 - 7.14.3 AstraZeneca (U.K.) IBS Treatment Major Product Offerings
 - 7.14.4 AstraZeneca (U.K.) IBS Treatment Revenue in Global Market (2017-2022)
 - 7.14.5 AstraZeneca (U.K.) Key News
- 7.15 Ipsen (France)
 - 7.15.1 Ipsen (France) Corporate Summary
 - 7.15.2 Ipsen (France) Business Overview
 - 7.15.3 Ipsen (France) IBS Treatment Major Product Offerings
 - 7.15.4 Ipsen (France) IBS Treatment Revenue in Global Market (2017-2022)

- 7.15.5 Ipsen (France) Key News
- 7.16 Novartis (Switzerland)
 - 7.16.1 Novartis (Switzerland) Corporate Summary
 - 7.16.2 Novartis (Switzerland) Business Overview
 - 7.16.3 Novartis (Switzerland) IBS Treatment Major Product Offerings
 - 7.16.4 Novartis (Switzerland) IBS Treatment Revenue in Global Market (2017-2022)
 - 7.16.5 Novartis (Switzerland) Key News
- 7.17 Takeda Pharmaceutical Company (Japan)
 - 7.17.1 Takeda Pharmaceutical Company (Japan) Corporate Summary
 - 7.17.2 Takeda Pharmaceutical Company (Japan) Business Overview
 - 7.17.3 Takeda Pharmaceutical Company (Japan) IBS Treatment Major Product Offerings
 - 7.17.4 Takeda Pharmaceutical Company (Japan) IBS Treatment Revenue in Global Market (2017-2022)
 - 7.17.5 Takeda Pharmaceutical Company (Japan) Key News
- 7.18 Synthetic Biologics (U.S.)
 - 7.18.1 Synthetic Biologics (U.S.) Corporate Summary
 - 7.18.2 Synthetic Biologics (U.S.) Business Overview
 - 7.18.3 Synthetic Biologics (U.S.) IBS Treatment Major Product Offerings
 - 7.18.4 Synthetic Biologics (U.S.) IBS Treatment Revenue in Global Market (2017-2022)
 - 7.18.5 Synthetic Biologics (U.S.) Key News
- 7.19 Protagonist Therapeutics (U.S.)
 - 7.19.1 Protagonist Therapeutics (U.S.) Corporate Summary
 - 7.19.2 Protagonist Therapeutics (U.S.) Business Overview
 - 7.19.3 Protagonist Therapeutics (U.S.) IBS Treatment Major Product Offerings
 - 7.19.4 Protagonist Therapeutics (U.S.) IBS Treatment Revenue in Global Market (2017-2022)
 - 7.19.5 Protagonist Therapeutics (U.S.) Key News
- 7.20 Pfizer (U.S.)
 - 7.20.1 Pfizer (U.S.) Corporate Summary
 - 7.20.2 Pfizer (U.S.) Business Overview
 - 7.20.3 Pfizer (U.S.) IBS Treatment Major Product Offerings
 - 7.20.4 Pfizer (U.S.) IBS Treatment Revenue in Global Market (2017-2022)
 - 7.20.5 Pfizer (U.S.) Key News
- 7.21 Lexicon Pharmaceuticals (U.S.)
 - 7.21.1 Lexicon Pharmaceuticals (U.S.) Corporate Summary
 - 7.21.2 Lexicon Pharmaceuticals (U.S.) Business Overview
 - 7.21.3 Lexicon Pharmaceuticals (U.S.) IBS Treatment Major Product Offerings

7.21.4 Lexicon Pharmaceuticals (U.S.) IBS Treatment Revenue in Global Market (2017-2022)

7.21.5 Lexicon Pharmaceuticals (U.S.) Key News

7.22 Innovate Biopharmaceuticals (U.S.)

7.22.1 Innovate Biopharmaceuticals (U.S.) Corporate Summary

7.22.2 Innovate Biopharmaceuticals (U.S.) Business Overview

7.22.3 Innovate Biopharmaceuticals (U.S.) IBS Treatment Major Product Offerings

7.22.4 Innovate Biopharmaceuticals (U.S.) IBS Treatment Revenue in Global Market (2017-2022)

7.22.5 Innovate Biopharmaceuticals (U.S.) Key News

8 CONCLUSION

9 APPENDIX

9.1 Note

9.2 Examples of Clients

9.3 Disclaimer

List Of Tables

LIST OF TABLES

- Table 1. IBS Treatment Market Opportunities & Trends in Global Market
- Table 2. IBS Treatment Market Drivers in Global Market
- Table 3. IBS Treatment Market Restraints in Global Market
- Table 4. Key Players of IBS Treatment in Global Market
- Table 5. Top IBS Treatment Players in Global Market, Ranking by Revenue (2021)
- Table 6. Global IBS Treatment Revenue by Companies, (US\$, Mn), 2017-2022
- Table 7. Global IBS Treatment Revenue Share by Companies, 2017-2022
- Table 8. Global Companies IBS Treatment Product Type
- Table 9. List of Global Tier 1 IBS Treatment Companies, Revenue (US\$, Mn) in 2021 and Market Share
- Table 10. List of Global Tier 2 and Tier 3 IBS Treatment Companies, Revenue (US\$, Mn) in 2021 and Market Share
- Table 11. By Type – Global IBS Treatment Revenue, (US\$, Mn), 2021 & 2028
- Table 12. By Type - IBS Treatment Revenue in Global (US\$, Mn), 2017-2022
- Table 13. By Type - IBS Treatment Revenue in Global (US\$, Mn), 2023-2028
- Table 14. By Application – Global IBS Treatment Revenue, (US\$, Mn), 2021 & 2028
- Table 15. By Application - IBS Treatment Revenue in Global (US\$, Mn), 2017-2022
- Table 16. By Application - IBS Treatment Revenue in Global (US\$, Mn), 2023-2028
- Table 17. By Region – Global IBS Treatment Revenue, (US\$, Mn), 2021 & 2028
- Table 18. By Region - Global IBS Treatment Revenue (US\$, Mn), 2017-2022
- Table 19. By Region - Global IBS Treatment Revenue (US\$, Mn), 2023-2028
- Table 20. By Country - North America IBS Treatment Revenue, (US\$, Mn), 2017-2022
- Table 21. By Country - North America IBS Treatment Revenue, (US\$, Mn), 2023-2028
- Table 22. By Country - Europe IBS Treatment Revenue, (US\$, Mn), 2017-2022
- Table 23. By Country - Europe IBS Treatment Revenue, (US\$, Mn), 2023-2028
- Table 24. By Region - Asia IBS Treatment Revenue, (US\$, Mn), 2017-2022
- Table 25. By Region - Asia IBS Treatment Revenue, (US\$, Mn), 2023-2028
- Table 26. By Country - South America IBS Treatment Revenue, (US\$, Mn), 2017-2022
- Table 27. By Country - South America IBS Treatment Revenue, (US\$, Mn), 2023-2028
- Table 28. By Country - Middle East & Africa IBS Treatment Revenue, (US\$, Mn), 2017-2022
- Table 29. By Country - Middle East & Africa IBS Treatment Revenue, (US\$, Mn), 2023-2028
- Table 30. Allergan (Ireland) Corporate Summary
- Table 31. Allergan (Ireland) IBS Treatment Product Offerings

- Table 32. Allergan (Ireland) IBS Treatment Revenue (US\$, Mn), (2017-2022)
- Table 33. Sucampo Pharmaceuticals (U.S.) Corporate Summary
- Table 34. Sucampo Pharmaceuticals (U.S.) IBS Treatment Product Offerings
- Table 35. Sucampo Pharmaceuticals (U.S.) IBS Treatment Revenue (US\$, Mn), (2017-2022)
- Table 36. Ironwood Pharmaceuticals (U.S.) Corporate Summary
- Table 37. Ironwood Pharmaceuticals (U.S.) IBS Treatment Product Offerings
- Table 38. Ironwood Pharmaceuticals (U.S.) IBS Treatment Revenue (US\$, Mn), (2017-2022)
- Table 39. Astellas Pharma (Japan) Corporate Summary
- Table 40. Astellas Pharma (Japan) IBS Treatment Product Offerings
- Table 41. Astellas Pharma (Japan) IBS Treatment Revenue (US\$, Mn), (2017-2022)
- Table 42. Bausch Health Corporate Summary
- Table 43. Bausch Health IBS Treatment Product Offerings
- Table 44. Bausch Health IBS Treatment Revenue (US\$, Mn), (2017-2022)
- Table 45. Abbott Laboratories (U.S.) Corporate Summary
- Table 46. Abbott Laboratories (U.S.) IBS Treatment Product Offerings
- Table 47. Abbott Laboratories (U.S.) IBS Treatment Revenue (US\$, Mn), (2017-2022)
- Table 48. Synergy Pharmaceuticals (U.S.) Corporate Summary
- Table 49. Synergy Pharmaceuticals (U.S.) IBS Treatment Product Offerings
- Table 50. Synergy Pharmaceuticals (U.S.) IBS Treatment Revenue (US\$, Mn), (2017-2022)
- Table 51. Ardelyx (U.S.) Corporate Summary
- Table 52. Ardelyx (U.S.) IBS Treatment Product Offerings
- Table 53. Ardelyx (U.S.) IBS Treatment Revenue (US\$, Mn), (2017-2022)
- Table 54. Nestle (Switzerland) Corporate Summary
- Table 55. Nestle (Switzerland) IBS Treatment Product Offerings
- Table 56. Nestle (Switzerland) IBS Treatment Revenue (US\$, Mn), (2017-2022)
- Table 57. Sebela Pharmaceuticals (Ireland) Corporate Summary
- Table 58. Sebela Pharmaceuticals (Ireland) IBS Treatment Product Offerings
- Table 59. Sebela Pharmaceuticals (Ireland) IBS Treatment Revenue (US\$, Mn), (2017-2022)
- Table 60. Probi (Sweden) Corporate Summary
- Table 61. Probi (Sweden) IBS Treatment Product Offerings
- Table 62. Probi (Sweden) IBS Treatment Revenue (US\$, Mn), (2017-2022)
- Table 63. Alfasigma USA (Italy) Corporate Summary
- Table 64. Alfasigma USA (Italy) IBS Treatment Product Offerings
- Table 65. Alfasigma USA (Italy) IBS Treatment Revenue (US\$, Mn), (2017-2022)
- Table 66. RedHill Biopharma (Israel) Corporate Summary

- Table 67. RedHill Biopharma (Israel) IBS Treatment Product Offerings
- Table 68. RedHill Biopharma (Israel) IBS Treatment Revenue (US\$, Mn), (2017-2022)
- Table 69. AstraZeneca (U.K) Corporate Summary
- Table 70. AstraZeneca (U.K) IBS Treatment Product Offerings
- Table 71. AstraZeneca (U.K) IBS Treatment Revenue (US\$, Mn), (2017-2022)
- Table 72. Ipsen (France) Corporate Summary
- Table 73. Ipsen (France) IBS Treatment Product Offerings
- Table 74. Ipsen (France) IBS Treatment Revenue (US\$, Mn), (2017-2022)
- Table 75. Novartis (Switzerland) Corporate Summary
- Table 76. Novartis (Switzerland) IBS Treatment Product Offerings
- Table 77. Novartis (Switzerland) IBS Treatment Revenue (US\$, Mn), (2017-2022)
- Table 78. Takeda Pharmaceutical Company (Japan) Corporate Summary
- Table 79. Takeda Pharmaceutical Company (Japan) IBS Treatment Product Offerings
- Table 80. Takeda Pharmaceutical Company (Japan) IBS Treatment Revenue (US\$, Mn), (2017-2022)
- Table 81. Synthetic Biologics (U.S.) Corporate Summary
- Table 82. Synthetic Biologics (U.S.) IBS Treatment Product Offerings
- Table 83. Synthetic Biologics (U.S.) IBS Treatment Revenue (US\$, Mn), (2017-2022)
- Table 84. Protagonist Therapeutics (U.S.) Corporate Summary
- Table 85. Protagonist Therapeutics (U.S.) IBS Treatment Product Offerings
- Table 86. Protagonist Therapeutics (U.S.) IBS Treatment Revenue (US\$, Mn), (2017-2022)
- Table 87. Pfizer (U.S.) Corporate Summary
- Table 88. Pfizer (U.S.) IBS Treatment Product Offerings
- Table 89. Pfizer (U.S.) IBS Treatment Revenue (US\$, Mn), (2017-2022)
- Table 90. Lexicon Pharmaceuticals (U.S.) Corporate Summary
- Table 91. Lexicon Pharmaceuticals (U.S.) IBS Treatment Product Offerings
- Table 92. Lexicon Pharmaceuticals (U.S.) IBS Treatment Revenue (US\$, Mn), (2017-2022)
- Table 93. Innovate Biopharmaceuticals (U.S.) Corporate Summary
- Table 94. Innovate Biopharmaceuticals (U.S.) IBS Treatment Product Offerings
- Table 95. Innovate Biopharmaceuticals (U.S.) IBS Treatment Revenue (US\$, Mn), (2017-2022)

List Of Figures

LIST OF FIGURES

- Figure 1. IBS Treatment Segment by Type in 2021
- Figure 2. IBS Treatment Segment by Application in 2021
- Figure 3. Global IBS Treatment Market Overview: 2021
- Figure 4. Key Caveats
- Figure 5. Global IBS Treatment Market Size: 2021 VS 2028 (US\$, Mn)
- Figure 6. Global IBS Treatment Revenue, 2017-2028 (US\$, Mn)
- Figure 7. The Top 3 and 5 Players Market Share by IBS Treatment Revenue in 2021
- Figure 8. By Type - Global IBS Treatment Revenue Market Share, 2017-2028
- Figure 9. By Application - Global IBS Treatment Revenue Market Share, 2017-2028
- Figure 10. By Region - Global IBS Treatment Revenue Market Share, 2017-2028
- Figure 11. By Country - North America IBS Treatment Revenue Market Share, 2017-2028
- Figure 12. US IBS Treatment Revenue, (US\$, Mn), 2017-2028
- Figure 13. Canada IBS Treatment Revenue, (US\$, Mn), 2017-2028
- Figure 14. Mexico IBS Treatment Revenue, (US\$, Mn), 2017-2028
- Figure 15. By Country - Europe IBS Treatment Revenue Market Share, 2017-2028
- Figure 16. Germany IBS Treatment Revenue, (US\$, Mn), 2017-2028
- Figure 17. France IBS Treatment Revenue, (US\$, Mn), 2017-2028
- Figure 18. U.K. IBS Treatment Revenue, (US\$, Mn), 2017-2028
- Figure 19. Italy IBS Treatment Revenue, (US\$, Mn), 2017-2028
- Figure 20. Russia IBS Treatment Revenue, (US\$, Mn), 2017-2028
- Figure 21. Nordic Countries IBS Treatment Revenue, (US\$, Mn), 2017-2028
- Figure 22. Benelux IBS Treatment Revenue, (US\$, Mn), 2017-2028
- Figure 23. By Region - Asia IBS Treatment Revenue Market Share, 2017-2028
- Figure 24. China IBS Treatment Revenue, (US\$, Mn), 2017-2028
- Figure 25. Japan IBS Treatment Revenue, (US\$, Mn), 2017-2028
- Figure 26. South Korea IBS Treatment Revenue, (US\$, Mn), 2017-2028
- Figure 27. Southeast Asia IBS Treatment Revenue, (US\$, Mn), 2017-2028
- Figure 28. India IBS Treatment Revenue, (US\$, Mn), 2017-2028
- Figure 29. By Country - South America IBS Treatment Revenue Market Share, 2017-2028
- Figure 30. Brazil IBS Treatment Revenue, (US\$, Mn), 2017-2028
- Figure 31. Argentina IBS Treatment Revenue, (US\$, Mn), 2017-2028
- Figure 32. By Country - Middle East & Africa IBS Treatment Revenue Market Share, 2017-2028

Figure 33. Turkey IBS Treatment Revenue, (US\$, Mn), 2017-2028

Figure 34. Israel IBS Treatment Revenue, (US\$, Mn), 2017-2028

Figure 35. Saudi Arabia IBS Treatment Revenue, (US\$, Mn), 2017-2028

Figure 36. UAE IBS Treatment Revenue, (US\$, Mn), 2017-2028

Figure 37. Allergan (Ireland) IBS Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 38. Sucampo Pharmaceuticals (U.S.) IBS Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 39. Ironwood Pharmaceuticals (U.S.) IBS Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 40. Astellas Pharma (Japan) IBS Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 41. Bausch Health IBS Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 42. Abbott Laboratories (U.S.) IBS Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 43. Synergy Pharmaceuticals (U.S.) IBS Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 44. Ardelyx (U.S.) IBS Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 45. Nestle (Switzerland) IBS Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 46. Sebela Pharmaceuticals (Ireland) IBS Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 47. Probi (Sweden) IBS Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 48. Alfasigma USA (Italy) IBS Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 49. RedHill Biopharma (Israel) IBS Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 50. AstraZeneca (U.K) IBS Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 51. Ipsen (France) IBS Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 52. Novartis (Switzerland) IBS Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 53. Takeda Pharmaceutical Company (Japan) IBS Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 54. Synthetic Biologics (U.S.) IBS Treatment Revenue Year Over Year Growth

(US\$, Mn) & (2017-2022)

Figure 55. Protagonist Therapeutics (U.S.) IBS Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 56. Pfizer (U.S.) IBS Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 57. Lexicon Pharmaceuticals (U.S.) IBS Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 58. Innovate Biopharmaceuticals (U.S.) IBS Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

I would like to order

Product name: IBS Treatment Market, Global Outlook and Forecast 2022-2028

Product link: <https://marketpublishers.com/r/IFD9982022E7EN.html>

Price: US\$ 3,250.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/IFD9982022E7EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970